

NEW DEMONSTRATION PROJECT

EFFECTIVE JAN. 1, 2005

- > Medicare has adopted a one-year demonstration program that will pay physicians **\$130 per patient per day if the patient receives chemotherapy by intravenous push or infusion** and the Medicare claim form provides information about the patients' nausea/vomiting, pain and fatigue.
- > To earn this extra payment, physicians will need to assess the patient's status with respect to nausea/vomiting, pain and fatigue and to report those assessments through a new series of 12 billing G codes that will supplement the normal billing codes.
- > Patients will be assessed with respect to each of the factors on a four-point scale- "not at all," "a little," "quite a bit," or "very much." Each level corresponds to a new G-code, and therefore three new G-codes will be included on the Medicare claim form to report the patient's status on each of the three factors.
- > Demonstration G-codes **probably will not** be recognized by other carriers.

DEMONSTRATION G-CODES FOR ASSESSMENT

	Nausea and/or Vomiting (Chemotherapy assessment for nausea and/or vomiting, patient reported, performed at the time of chemotherapy administration)	Pain (Chemotherapy assessment for pain, patient reported, performed at the time of chemotherapy administration)	Lack of Energy (Fatigue) (Chemotherapy assessment for lack of energy (fatigue), patient reported, performed at the time of chemotherapy administration)
G-code for Assessment Level 1 – not at all	G9021	G9025	G9029
G-code for Assessment Level 2 – a little	G9022	G9026	G9030
G-code for Assessment Level 3 – quite a bit	G9023	G9027	G9031
G-code for Assessment Level 4 – very much	G9024	G9028	G9032

Preparing now for Jan. 1, 2005

- > Practices may change their encounter forms to include G-codes to capture all services rendered.
- > Modifier 59 and codes 96408 and 96410 will be obsolete beginning January 1, 2005. (modifier 59 may only be used to bill for hydration provided on the same day as chemotherapy.)
- > Only Modifier 25 for an E&M office service will remain in use.
- > Oncology Associates will be sending up-to-the-minute information on these changes as soon as we receive them.
- > Visit www.asco.org for a list of frequently asked questions. Go to the MMA Special Alert link on the homepage, then the frequently asked questions link.

Please contact Oncology Associates at 888-732-7352 with any questions. **OA**

